A nationwide observational study in heavily pretreated metastatic HER2-positive breast cancer patients.

Asbjørn Due Tobias BergMaj-Britt JensenSophie YammeniLone VolmerAnne Sofie Brems-EskildsenKlaus Kaae AndersenSaeeda RanaAnn KnoopIben Kümler

Published in: Acta oncologica (Stockholm, Sweden) (2023)

In this real-world study, we found that patients were treated with a wide variety of anti-cancer agents with modest efficacy. However, patients in this study did not have access to newer therapies like tucatinib and T-DXd.

Keyphrases

end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
small cell lung cancer
peritoneal dialysis
squamous cell carcinoma
prognostic factors